| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Cynthia D J Kusters, Kimberly C Paul, Ilaria Guella, Jeff M Bronstein, Janet S Sinsheimer, Matt J Farrer, Beate R Rit. Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease. Parkinsonism & related disorders. vol 47. 2019-04-12. PMID:29191473. |
dopamine receptors and bdnf-haplotypes predict dyskinesia in parkinson's disease. |
2019-04-12 |
2023-08-13 |
Not clear |
| Cynthia D J Kusters, Kimberly C Paul, Ilaria Guella, Jeff M Bronstein, Janet S Sinsheimer, Matt J Farrer, Beate R Rit. Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease. Parkinsonism & related disorders. vol 47. 2019-04-12. PMID:29191473. |
we examined the influence of haplotypes in three dopamine receptors (drd1, drd2 and drd3) and the brain derived neurotrophic factor (bdnf) on dyskinesia. |
2019-04-12 |
2023-08-13 |
Not clear |
| Jared T Hinkle, Kate Perepezko, Liana S Rosenthal, Kelly A Mills, Alexander Pantelyat, Zoltan Mari, Laura Tochen, Jee Yun Bang, Medha Gudavalli, Nadine Yoritomo, Ankur Butala, Catherine C Bakker, Vanessa Johnson, Emile Moukheiber, Ted M Dawson, Gregory M Ponton. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism & related disorders. vol 47. 2019-04-12. PMID:29198499. |
markers of impaired motor and cognitive volition in parkinson's disease: correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. |
2019-04-12 |
2023-08-13 |
Not clear |
| Melissa M Conti, Nicole Chambers, Christopher Bisho. A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia. Neuroscience and biobehavioral reviews. vol 92. 2019-02-11. PMID:29782883. |
traditionally, dopamine (da) and acetylcholine (ach) striatal systems were considered antagonistic and imbalances or aberrant signaling between these neurotransmitter systems could be detrimental to basal ganglia activity and pursuant motor function, such as in parkinson's disease (pd) and l-dopa-induced dyskinesia (lid). |
2019-02-11 |
2023-08-13 |
Not clear |
| Sara Sanz-Blasco, Melina P Bordone, Ana Damianich, Gimena Gomez, M Alejandra Bernardi, Luciana Isaja, Irene R Taravini, Diane P Hanger, M Elena Avale, Oscar S Gershanik, Juan E Ferrari. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease. Molecular neurobiology. vol 55. issue 6. 2019-02-04. PMID:28840468. |
dopamine replacement therapy with l-dopa is the treatment of choice for parkinson's disease; however, its long-term use is frequently associated with l-dopa-induced dyskinesia (lid). |
2019-02-04 |
2023-08-13 |
mouse |
| Omar S Mabrou. Delta Opioid Pharmacology in Parkinson's Disease. Handbook of experimental pharmacology. vol 247. 2019-01-22. PMID:27718057. |
exogenous dopamine replacement brings about additional challenges since after years of treatment it almost invariably gives rise to dyskinesia as a side effect. |
2019-01-22 |
2023-08-13 |
Not clear |
| Claude Rouillard, Joanie Baillargeon, Brigitte Paquet, Michel St-Hilaire, Jérôme Maheux, Catherine Lévesque, Noémie Darlix, Simon Majeur, Daniel Lévesqu. Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease. Experimental neurology. vol 304. 2019-01-07. PMID:29530712. |
genetic disruption of the nuclear receptor nur77 (nr4a1) in rat reduces dopamine cell loss and l-dopa-induced dyskinesia in experimental parkinson's disease. |
2019-01-07 |
2023-08-13 |
rat |
| Claude Rouillard, Joanie Baillargeon, Brigitte Paquet, Michel St-Hilaire, Jérôme Maheux, Catherine Lévesque, Noémie Darlix, Simon Majeur, Daniel Lévesqu. Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease. Experimental neurology. vol 304. 2019-01-07. PMID:29530712. |
collectively, these results suggest that nr4a1 is involved in dopamine cell loss and l-dopa-induced dyskinesia in experimental pd. |
2019-01-07 |
2023-08-13 |
rat |
| Matthieu F Bastide, Christelle Glangetas, Evelyne Doudnikoff, Qin Li, Mathieu Bourdenx, Pierre-Olivier Fernagut, Éric C Dumont, François Georges, Erwan Bézar. Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia. Scientific reports. vol 7. issue 1. 2018-12-17. PMID:28539659. |
a whole brain immediate early gene mapping highlighted the dorsolateral bed nucleus of the stria terminalis (dlbst) as a structure putatively involved in l-3,4-dihydroxyphenylalanine (l-dopa)-induced dyskinesia (lid), the debilitating side-effects of chronic dopamine replacement therapy in parkinson's disease (pd). |
2018-12-17 |
2023-08-13 |
rat |
| G C Nascimento, K Bariotto-Dos-Santos, C R A Leite-Panissi, E A Del-Bel, M Bortolanz. Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats. Neurotoxicity research. vol 34. issue 4. 2018-11-26. PMID:29611150. |
the dopamine precursor, l-dopa (l-3,4-dihydroxyphenylalanine), the classic therapy for pd, seems to be effective in pain threshold; however, there are no studies correlating l-dopa-induced dyskinesia (lid) and nociception development in experimental parkinsonism. |
2018-11-26 |
2023-08-13 |
rat |
| Silvia Picazio, Viviana Ponzo, Carlo Caltagirone, Livia Brusa, Giacomo Koc. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias. Journal of neurology. vol 265. issue 9. 2018-11-26. PMID:29980853. |
chronic dopamine replacement therapies in parkinson's disease can induce side effects, such as levodopa-induced dyskinesias and impulse control disorders. |
2018-11-26 |
2023-08-13 |
Not clear |
| Jones G Parker, Jesse D Marshall, Biafra Ahanonu, Yu-Wei Wu, Tony Hyun Kim, Benjamin F Grewe, Yanping Zhang, Jin Zhong Li, Jun B Ding, Michael D Ehlers, Mark J Schnitze. Diametric neural ensemble dynamics in parkinsonian and dyskinetic states. Nature. vol 557. issue 7704. 2018-10-15. PMID:29720658. |
the opposite imbalance might underlie hyperkinetic abnormalities, such as dyskinesia caused by treatment of parkinson's disease with the dopamine precursor l-dopa. |
2018-10-15 |
2023-08-13 |
mouse |
| Jones G Parker, Jesse D Marshall, Biafra Ahanonu, Yu-Wei Wu, Tony Hyun Kim, Benjamin F Grewe, Yanping Zhang, Jin Zhong Li, Jun B Ding, Michael D Ehlers, Mark J Schnitze. Diametric neural ensemble dynamics in parkinsonian and dyskinetic states. Nature. vol 557. issue 7704. 2018-10-15. PMID:29720658. |
here we monitored thousands of spns in behaving mice, before and after dopamine depletion and during l-dopa-induced dyskinesia. |
2018-10-15 |
2023-08-13 |
mouse |
| Han Soo Yoo, Seok Jong Chung, Su Jin Chung, Hyojeong Moon, Jung Su Oh, Jae Seung Kim, Jin Yong Hong, Byoung Seok Ye, Young Ho Sohn, Phil Hyu Le. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease. European journal of nuclear medicine and molecular imaging. vol 45. issue 3. 2018-10-09. PMID:29075830. |
presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in parkinson's disease. |
2018-10-09 |
2023-08-13 |
Not clear |
| Adrian Newman-Tancredi, Mark A Varney, Andrew C McCrear. Effects of the Serotonin 5-HT Neurochemical research. vol 43. issue 5. 2018-09-27. PMID:29572645. |
effects of the serotonin 5-ht peak-dose dyskinesia is associated with the dramatic increase in striatal dopamine levels that follows l-dopa administration. |
2018-09-27 |
2023-08-13 |
Not clear |
| Masahiko Tomiyam. [Symptoms and Pathophysiology of Dyskinesias]. Brain and nerve = Shinkei kenkyu no shinpo. vol 69. issue 12. 2018-06-08. PMID:29282344. |
the priming process involved in peak-dose dyskinesia is as follows: (1) marked fluctuation of dopamine concentration occurs in the synaptic clefts of striatal neurons after each levodopa dose, (2) cortico-striatal synapses of the striatal spiny neurons of the direct pathway become supersensitive, (3) there is increased production of gaba in the spiny neurons and excessive storage of gaba in their axon terminals, (4) following this, each dose of levodopa causes excessive release of gaba into the output nuclei of the basal ganglia, resulting in abnormal firing of the neurons in these nuclei. |
2018-06-08 |
2023-08-13 |
Not clear |
| X Zhou, J Doorduin, P H Elsinga, R A J O Dierckx, E F J de Vries, C Casteel. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia. NeuroImage. vol 157. 2018-05-28. PMID:28583881. |
altered adenosine 2a and dopamine d2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia. |
2018-05-28 |
2023-08-13 |
rat |
| Jonathan Timpka, Bianca Nitu, Veronika Datieva, Per Odin, Angelo Antonin. Device-Aided Treatment Strategies in Advanced Parkinson's Disease. International review of neurobiology. vol 132. 2018-03-19. PMID:28554418. |
device-aided parkinson (pd) therapies refer to deep brain stimulation (dbs), levodopa-carbidopa intestinal gel infusion (lcig), and subcutaneous infusion of the dopamine agonist apomorphine and represent effective strategies counteracting motor fluctuations and dyskinesia. |
2018-03-19 |
2023-08-13 |
Not clear |
| C Laloux, F Gouel, C Lachaud, K Timmerman, B Do Van, A Jonneaux, M Petrault, G Garcon, N Rouaix, C Moreau, R Bordet, J A Duce, J C Devedjian, D Devo. Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease? Neurobiology of disease. vol 103. 2018-03-02. PMID:28363801. |
continuous cerebroventricular administration of dopamine: a new treatment for severe dyskinesia in parkinson's disease? |
2018-03-02 |
2023-08-13 |
mouse |
| Francesco Bez, Veronica Francardo, M Angela Cenc. Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion. Neurobiology of disease. vol 94. 2018-02-27. PMID:27312773. |
dramatic differences in susceptibility to l-dopa-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion. |
2018-02-27 |
2023-08-13 |
mouse |